This represents an NNT of 125. The two drugs were about equally effective at treating RA symptoms. Helicobacter pylori was not a significant risk factor for development of clinical GI events in either arm of the study. She noted that while the absolute reductions in GI events were small, their impact is significant because of the high prevalence of osteoarthritis and rheumatoid arthritis. It's good news for the patients, because we're able to control their pain without the risk of GI complications.
Rofecoxib is approved in Canada for acute pain in patients with osteoarthritis.
Manufacturer Merck Frosst is now filing for approval of the drug for rheumatoid arthritis.